Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9818668 | 0.98 | CNR1 (0.70) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818691 | 0.89 | CNR1 (0.66) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818621 | 0.89 | CNR1 (0.66) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818669 | 0.89 | CNR1 (0.87) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818576 | 0.89 | LMNA (0.68) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818724 | 0.87 | CNR1 (0.63) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818592 | 0.87 | CNR1 (0.63) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818721 | 0.87 | CNR1 (0.63) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818643 | 0.86 | MAPT (0.56) | CNR1LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL9818694 | 0.86 | CNR1 (0.62) | CNR1L3MBTL1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 705 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517900-B2 | Pyrazole derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | claimed |
| EP-1670460-A4 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1653962-A4 | PYRAZINE MODULATORS OF CANNABINOID RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-11 | — | — | EP | claimed |
| EP-1644335-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | claimed |
| EP-1644370-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-04 | — | — | EP | claimed |
| JP-2007514770-A | — | — | 2007-06-07 | — | — | JP | claimed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | claimed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | claimed |
| EP-1697370-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | claimed |
| EP-1697371-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005063762-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BROSTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | claimed |
| WO-2005037199-A2 | PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-28 | — | — | WO | claimed |
| US-20050080087-A1 | Pyrazole derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | claimed |
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | claimed |
| WO-2005016286-A2 | PYRAZINE MODULATORS OF CANNABINOID RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005007111-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2005007628-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-27 | — | — | WO | claimed |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-20 | — | — | US | claimed |
| US-20050009870-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009870-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | CNR1 2/4885LMNA 4479/4885L3MBTL1 4811/4885 |
| US-20050080087-A1 | Pyrazole derivatives as cannabinoid receptor modulators | CNR1, CNR2, NPY1R | CNR1 1/4885LMNA 4126/4885L3MBTL1 4614/4885 |
| US-20050014786-A1 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | CNR1 2/4885LMNA 4479/4885L3MBTL1 4811/4885 |
| US-20050143381-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, CCKBR | CNR1 1/4885LMNA 3559/4885L3MBTL1 4650/4885 |
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | CNR1, CNR2, GPR18 | CNR1 1/4885LMNA 3907/4885L3MBTL1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.